Interestingly, we recently found that some 3-styrylchromone derivatives, which have already been identified to have anti-cancer activities [58], have weak anti-inflammatory activities via the suppression of HMGB1-RAGE [59] and lipopolysaccharide-Toll-like receptor (TLR)4 [60] signaling pathways in macrophage-like RAW264.7 cells. Here, HMGB1 is linked to cancer.